Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Cyteir Therapeutics stock price, quote, forecast and news

CYT
US23284P1030

Price

3.01
Today +/-
+0
Today %
+0 %
P

Cyteir Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cyteir Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cyteir Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cyteir Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cyteir Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cyteir Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cyteir Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cyteir Therapeutics’s growth potential.

Cyteir Therapeutics Revenue, EBIT and net profit per share

DateCyteir Therapeutics RevenueCyteir Therapeutics EBITCyteir Therapeutics Net Income
2025e0 undefined-55.95 M undefined-31.27 M undefined
2024e0 undefined5.06 M undefined-31.63 M undefined
2023e0 undefined-43.79 M undefined-39.27 M undefined
20220 undefined-48.17 M undefined-46.06 M undefined
20210 undefined-42.26 M undefined-42.13 M undefined
20200 undefined-20.94 M undefined-20.82 M undefined
201910,000 undefined-16.11 M undefined-15.04 M undefined

Cyteir Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20192020202120222023e2024e2025e
0000000
-------
-------
0000000
-16-20-42-48-435-55
-------
-15-20-42-46-39-31-31
-33.33110.009.52-15.22-20.51-
34.4734.4735.2235.27000
-------
Details

Keystats

ⓘ

Revenue and Growth

The Cyteir Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cyteir Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cyteir Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cyteir Therapeutics's financial health and stability.

Assets

Cyteir Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cyteir Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cyteir Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cyteir Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2019202020212022
-15-20-42-46
0000
0000
-212-2
00610
0000
0000
-17-18-36-42
00-10
00-10
0000
0000
0000
3612160
3612160
----
0000
19-17178-42
-17.69-19.39-37.22-42.84
0000

Cyteir Therapeutics stock margins

The Cyteir Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cyteir Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cyteir Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cyteir Therapeutics's sales revenue. A higher gross margin percentage indicates that the Cyteir Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cyteir Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cyteir Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cyteir Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cyteir Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cyteir Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cyteir Therapeutics Margin History

Cyteir Therapeutics Gross marginCyteir Therapeutics Profit marginCyteir Therapeutics EBIT marginCyteir Therapeutics Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %-161,100.01 %-150,400 %

Cyteir Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Cyteir Therapeutics earnings per share therefore indicates how much revenue Cyteir Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cyteir Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cyteir Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cyteir Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cyteir Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cyteir Therapeutics Revenue, EBIT and net profit per share

DateCyteir Therapeutics Sales per ShareCyteir Therapeutics EBIT per shareCyteir Therapeutics Earnings per Share
2025e0 undefined0 undefined-0.87 undefined
2024e0 undefined0 undefined-0.88 undefined
2023e0 undefined0 undefined-1.09 undefined
20220 undefined-1.37 undefined-1.31 undefined
20210 undefined-1.2 undefined-1.2 undefined
20200 undefined-0.61 undefined-0.6 undefined
20190 undefined-0.47 undefined-0.44 undefined

Cyteir Therapeutics business model

Cyteir Therapeutics is one of the most popular companies on Eulerpool.com.

Cyteir Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Cyteir Therapeutics shares outstanding

The number of shares was Cyteir Therapeutics in 2023 — This indicates how many shares 35.27 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cyteir Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cyteir Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cyteir Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cyteir Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Cyteir Therapeutics.

Cyteir Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.32 -0.24  (25.74 %)2023 Q2
3/31/2023-0.27 -0.35  (-29.77 %)2023 Q1
12/31/2022-0.35 -0.25  (27.72 %)2022 Q4
9/30/2022-0.41 -0.31  (25.14 %)2022 Q3
6/30/2022-0.44 -0.34  (23.49 %)2022 Q2
3/31/2022-0.39 -0.4  (-1.55 %)2022 Q1
12/31/2021-0.4 -0.34  (14.55 %)2021 Q4
9/30/2021-0.36 -0.33  (9.24 %)2021 Q3
6/30/2021-1.47 -4.83  (-227.55 %)2021 Q2
1

Eulerpool ESG Scorecard© for the Cyteir Therapeutics stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

61

👫 Social

41

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cyteir Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.82 % Droia Ventures3,536,803010/5/2023
9.05 % Venrock3,259,022010/5/2023
9.03 % BML Capital Management LLC3,250,008012/31/2023
8.39 % Newtyn Management, LLC3,021,500521,05612/31/2023
7.04 % Gabelli Funds, LLC2,535,935399,8852/8/2024
6.83 % OUP Management Co., LLC2,459,57209/30/2023
6.79 % Lightstone Ventures II LP2,444,265010/5/2023
6.53 % Hedgehog Capital, L.L.C.2,350,385250,50312/31/2023
3.05 % Anson Funds Management LP.1,096,422-227,69212/31/2023
3.01 % Renschler (Markus F)1,082,21393,47711/20/2023
1
2
3
4
5
...
10

Cyteir Therapeutics Executives and Management Board

Dr. Markus Renschler61
Cyteir Therapeutics President, Chief Executive Officer, Director (since 2016)
Compensation 1.2 M
Mr. John Thero
Cyteir Therapeutics Independent Director
Compensation 172,074
Mr. Stephen Sands
Cyteir Therapeutics Independent Director
Compensation 164,214
Mr. Joseph Zakrzewski60
Cyteir Therapeutics Independent Chairman of the Board
Compensation 145,461
Ms. Jean George64
Cyteir Therapeutics Independent Director
Compensation 114,461
1
2

Cyteir Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ryvu Therapeutics Stock
Ryvu Therapeutics
SupplierCustomer0,940,940,810,82--
IDEAYA Biosciences Stock
IDEAYA Biosciences
SupplierCustomer0,860,920,910,93--
AbbVie Stock
AbbVie
SupplierCustomer0,610,82-0,46-0,89--
Clovis Oncology Stock
Clovis Oncology
SupplierCustomer0,610,74-0,160,82--
Rain Therapeutics Stock
Rain Therapeutics
SupplierCustomer0,480,740,620,92--
Roche Holding Stock
Roche Holding
SupplierCustomer0,420,88-0,370,17--
BeiGene Stock
BeiGene
SupplierCustomer0,270,810,700,97--
Repare Therapeutics Stock
Repare Therapeutics
SupplierCustomer0,130,120,790,95--
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,120,69-0,73-0,88--
Tango Therapeutics Stock
Tango Therapeutics
SupplierCustomer0,120,570,800,86--
1
2

Most common questions regarding Cyteir Therapeutics

What is the P/E ratio of Cyteir Therapeutics 2024?

The Cyteir Therapeutics P/E ratio is -3.36.

What is the P/S ratio of Cyteir Therapeutics 2024?

The Cyteir Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Cyteir Therapeutics?

The AlleAktien quality score for Cyteir Therapeutics is 2/10.

What is the revenue of Cyteir Therapeutics 2024?

The revenue cannot currently be calculated for Cyteir Therapeutics.

How high is the profit of Cyteir Therapeutics 2024?

The expected Cyteir Therapeutics profit is -31.63 M USD.

What is the business model of Cyteir Therapeutics

No history available for Cyteir Therapeutics.

What is the Cyteir Therapeutics dividend?

Cyteir Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Cyteir Therapeutics pay dividends?

The dividend cannot currently be calculated for Cyteir Therapeutics or the company does not pay out a dividend.

What is the Cyteir Therapeutics ISIN?

The ISIN of Cyteir Therapeutics is US23284P1030.

What is the Cyteir Therapeutics ticker?

The ticker of Cyteir Therapeutics is CYT.

How much dividend does Cyteir Therapeutics pay?

Over the past 12 months, Cyteir Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cyteir Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyteir Therapeutics?

The current dividend yield of Cyteir Therapeutics is .

When does Cyteir Therapeutics pay dividends?

Cyteir Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyteir Therapeutics?

Cyteir Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cyteir Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyteir Therapeutics located?

Cyteir Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyteir Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyteir Therapeutics from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did Cyteir Therapeutics pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of Cyteir Therapeutics in the year 2023?

In the year 2023, Cyteir Therapeutics distributed 0 USD as dividends.

In which currency does Cyteir Therapeutics pay out the dividend?

The dividends of Cyteir Therapeutics are distributed in USD.

All fundamentals about Cyteir Therapeutics

Our stock analysis for Cyteir Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyteir Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.